BIOMAT Database Logo BIOMAT Database Logo

Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1. 2013

Huihui Chong, and Xue Yao, and Zonglin Qiu, and Jianping Sun, and Meng Zhang, and Sandro Waltersperger, and Meitian Wang, and Shan-Lu Liu, and Sheng Cui, and Yuxian He
Chinese Academy of Medical Sciences, 9 Dong Dan San Tiao, Beijing 100730, China.

Peptides derived from the C-terminal heptad repeat (C peptides) of HIV-1 gp41 are potent inhibitors against virus entry. However, development of a short C peptide possessing high anti-HIV potency is considered a daunting challenge. We recently discovered that the residues Met626 and Thr627 preceding the pocket-binding domain of the C peptide adopt a unique M-T hook structure that is crucial for the design of HIV-1 fusion inhibitors. In this study, we first presented a proof-of-concept prototype that the M-T hook residues can dramatically improve the antiviral activity and thermostability of a short C peptide. We then generated a 24-mer peptide termed MT-SC22EK by incorporating the M-T hook structure to the N terminus of the poorly active short C peptide SC22EK. Amazingly, MT-SC22EK inhibited HIV-1-mediated cell fusion and infection at a level comparable to C34, T1249, SC29EK, and sifuvirtide, and it was highly active against diverse HIV-1 subtypes and variants, including those T20 (enfuvirtide) and SC29EK-resistant viruses. The high-resolution crystal structure of MT-SC22EK reveals the N-terminal M-T hook conformation folded by incorporated Met626 and Thr627 and identifies the C-terminal boundary critical for the anti-HIV activity. Collectively, our studies provide new insights into the mechanisms of HIV-1 fusion and its inhibition.

UI MeSH Term Description Entries
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077560 Enfuvirtide A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS. DP 178,DP-178,DP178,Fuzeon,Pentafuside,Peptide T20,T20 Peptide,T20, Peptide
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015700 HIV Envelope Protein gp41 Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING. Envelope Protein gp41, HIV,HIV Transmembrane Protein gp41,HTLV-III gp41,env Protein gp41, HIV,gp41(HIV),gp41 Envelope Protein, HIV
D017433 Protein Structure, Secondary The level of protein structure in which regular hydrogen-bond interactions within contiguous stretches of polypeptide chain give rise to ALPHA-HELICES; BETA-STRANDS (which align to form BETA-SHEETS), or other types of coils. This is the first folding level of protein conformation. Secondary Protein Structure,Protein Structures, Secondary,Secondary Protein Structures,Structure, Secondary Protein,Structures, Secondary Protein

Related Publications

Huihui Chong, and Xue Yao, and Zonglin Qiu, and Jianping Sun, and Meng Zhang, and Sandro Waltersperger, and Meitian Wang, and Shan-Lu Liu, and Sheng Cui, and Yuxian He
Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1.
November 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Huihui Chong, and Xue Yao, and Zonglin Qiu, and Jianping Sun, and Meng Zhang, and Sandro Waltersperger, and Meitian Wang, and Shan-Lu Liu, and Sheng Cui, and Yuxian He
Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.
October 2008, Proceedings of the National Academy of Sciences of the United States of America,
Huihui Chong, and Xue Yao, and Zonglin Qiu, and Jianping Sun, and Meng Zhang, and Sandro Waltersperger, and Meitian Wang, and Shan-Lu Liu, and Sheng Cui, and Yuxian He
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
January 1997, Journal of medicinal chemistry,
Huihui Chong, and Xue Yao, and Zonglin Qiu, and Jianping Sun, and Meng Zhang, and Sandro Waltersperger, and Meitian Wang, and Shan-Lu Liu, and Sheng Cui, and Yuxian He
Current peptide HIV type-1 fusion inhibitors.
September 2009, Antiviral chemistry & chemotherapy,
Huihui Chong, and Xue Yao, and Zonglin Qiu, and Jianping Sun, and Meng Zhang, and Sandro Waltersperger, and Meitian Wang, and Shan-Lu Liu, and Sheng Cui, and Yuxian He
Novel indole based NNRTIs with improved potency against wild type and resistant HIV.
September 2014, Bioorganic & medicinal chemistry letters,
Huihui Chong, and Xue Yao, and Zonglin Qiu, and Jianping Sun, and Meng Zhang, and Sandro Waltersperger, and Meitian Wang, and Shan-Lu Liu, and Sheng Cui, and Yuxian He
Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
February 2018, European journal of medicinal chemistry,
Huihui Chong, and Xue Yao, and Zonglin Qiu, and Jianping Sun, and Meng Zhang, and Sandro Waltersperger, and Meitian Wang, and Shan-Lu Liu, and Sheng Cui, and Yuxian He
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.
July 2007, Proceedings of the National Academy of Sciences of the United States of America,
Huihui Chong, and Xue Yao, and Zonglin Qiu, and Jianping Sun, and Meng Zhang, and Sandro Waltersperger, and Meitian Wang, and Shan-Lu Liu, and Sheng Cui, and Yuxian He
Multitargeted drug design strategy for discovery of short-peptide-based HIV-1 entry inhibitors with high potency.
April 2023, European journal of medicinal chemistry,
Huihui Chong, and Xue Yao, and Zonglin Qiu, and Jianping Sun, and Meng Zhang, and Sandro Waltersperger, and Meitian Wang, and Shan-Lu Liu, and Sheng Cui, and Yuxian He
Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.
April 2003, Journal of medicinal chemistry,
Huihui Chong, and Xue Yao, and Zonglin Qiu, and Jianping Sun, and Meng Zhang, and Sandro Waltersperger, and Meitian Wang, and Shan-Lu Liu, and Sheng Cui, and Yuxian He
Enfuvirtide, an HIV-1 fusion inhibitor.
October 2003, The New England journal of medicine,
Copied contents to your clipboard!